What's in EndoCeutics Inc.'s pipeline?

EndoCeutics Inc. has 5 drugs in our index: 0 marketed, 0 filed, 5 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with EndoCeutics Inc.'s portfolio?

Top competitors by shared drug class: Boston Children's Hospital, Hospital Clinic of Barcelona.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/endoceutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

EndoCeutics Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EndoCeutics Inc. pipeline: 0 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 5 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
DHEA and Acolbifene	DHEA and Acolbifene	phase 3	Selective estrogen receptor modulator (SERM) combination	Estrogen receptor alpha and beta	Women's Health / Endocrinology
DHEA (0.5%)	DHEA (0.5%)	phase 3	Prohormone; hormone replacement therapy	Androgen receptor; estrogen receptor (via local conversion)	Gynecology; Menopause
DHEA (0.25%)	DHEA (0.25%)	phase 3	Hormone replacement therapy / Prohormone	Estrogen receptor, Androgen receptor (via local conversion)	Women's Health / Gynecology
Prasterone (DHEA)	Prasterone (DHEA)	phase 3	Steroid hormone precursor	Estrogen receptor (ER), Androgen receptor (AR)	Women's Health / Gynecology
DHEA (1.0%)	DHEA (1.0%)	phase 3	Steroid hormone / Prohormone	Androgen receptor, Estrogen receptor (via peripheral conversion)	Endocrinology / Women's Health

Therapeutic area mix

Women's Health / Gynecology · 2
Endocrinology / Women's Health · 1
Gynecology; Menopause · 1
Women's Health / Endocrinology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Boston Children's Hospital · 1 shared drug class
Hospital Clinic of Barcelona · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for EndoCeutics Inc.:

Cite this brief

Drug Landscape (2026). EndoCeutics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/endoceutics-inc. Accessed 2026-06-10.